Publicacións en colaboración con investigadores/as de Pfizer (United States) (10)

2022

  1. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

    Endocrine, Vol. 75, Núm. 2, pp. 525-536

2020

  1. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain

    Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 20, Núm. 1, pp. 105-114

2019

  1. Treatment adherence to pegvisomant in patients with acromegaly in Spain: PEGASO study

    Pituitary, Vol. 22, Núm. 2, pp. 137-145

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

2016

  1. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY

    Pituitary, Vol. 19, Núm. 2, pp. 127-137

2009

  1. Lipoatrophy in GH deficient patients treated with a long-acting pegylated GH

    European Journal of Endocrinology, Vol. 161, Núm. 4, pp. 533-540

2006

  1. Análisis coste-efectividad del uso de atorvastatina en pacientes diabéticos de tipo 2: Modelo farmacoeconómico del estudio CARDS

    Anales de Medicina Interna, Vol. 23, Núm. 5, pp. 213-219

  2. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life?

    European Journal of Endocrinology, Vol. 155, Núm. 1, pp. 109-119

2005

  1. Traumatic brain injury as a relevant cause of growth hormone deficiency in adults: A KIMS-based study

    Archives of Physical Medicine and Rehabilitation, Vol. 86, Núm. 3, pp. 463-468

2000

  1. A comparative evaluation of amlodipine and hydrochlorothiazide as monotherapy in the treatment of isolated systolic hypertension in the elderly

    Clinical Drug Investigation, Vol. 19, Núm. 5, pp. 317-326